Circulogix In Action
Circulogix Inc is focused on the development of innovative technologies to enable morphologic, molecular and functional characterization of rare cells for patient benefit in variety of disease settings.
Circulating Tumor Cell (CTC) Identification
Using a Pan-Cytokeratin (CK) antibody (green), CD45 antibody (red, not shown), and DAPI for nuclear visualization (blue), CTCs present on the CyteCatch slides are identified as nucleated, CK positive, CD45 negative cells with size and morphologic criteria consistent with malignancy.
Pictured: CTCs captured onto CyteCatch slides from a metastatic ovarian cancer patient.
Molecular Characterization of CTCs by In-Situ Hybridization (FISH or RNA ISH)
DNA aberrations, including gene copy number, chromosomal rearrangement and gene fusion, are a hallmark tumor initiation and progression for multiple disease types. The detection of these aberrations by FISH on CTCs could help predict the efficacy of numerous therapies designed to specifically target such anomalies.
Pictured: "Breakapart" FISH assay detecting a split signal of the ALK gene in a CTC enriched onto a CyteCatch slide from a metastatic, non-small cell lung cancer patient positive for ALK rearrangement.
Characterization of CTC Clusters
Although seminal studies demonstrate the prognostic and predictive value of CTCs as singular events, a growing body of evidence suggests that CTC clusters protect cells from anoikis, confer greater resistance to cytotoxic therapies, and increase the likelihood for successfully colonizing tumors at secondary sites.
Pictured: A cluster of nucleated, CK positive, CD45 negative CTCs enriched onto a CyteCatch slide from a metastatic breast cancer patient.
Viable CTC Enrichment for Functional Characterization
The standard workflow protocol for rare cell enrichment calls for a brief fixation step, which limits the ability to perform analyses requiring cell viability. By precise modification of the CyteCatch slide pore architecture, our proprietary technology at Circulogix permits the enrichment of viable CTCs for downstream functional applications.
Pictured: Scanning electron micrograph of a live tumor cell captured on a viable CyteCatch slide.
Identification of Circulating Cancer Associated Fibroblasts (cCAFs)
Recent evidence indicates that CAFs detected in the blood of cancer patients are associated with the presence of metastases, identifying them as potentially relevant clinical biomarker for poor prognosis.
Pictured: Multimarker IF labeling a cluster of nucleated (DAPI; Blue) CTCs (Pan CK; Green), cCAFs (Fibroblast Activation Protein; Red) captured on a CyteCatch slide from a metastatic breast cancer patient.
Photo courtesy of Dorraya El-Ashry, PhD.
Urine-Based Cytology
Standard cytology for the detection of atypical cells in voided urine from bladder cancer patients commonly contains non-tumor blood cells and other debris that limit interpretation by a pathologist. Sample processing by the FaCTChecker eliminates these materials, allowing for diagnoses to be more easily made, specifically in cases where background contaminants severely limits sample evaluation.
Pictured: PAP stain of Atypical urothelial tumor cells from a bladder cancer patient enriched onto a CyteCatch slide, where cell morphology is clearly presented and confounding background is significantly reduced.
The Team
Leadership at Circulogix
Ram Datar, MPhil, PhD
Chief Executive Officer
Siddarth Rawal, MD
Chief Operating Officer
Anthony Williams, PhD
Chief Scientific Officer
Sung-Jin Kim, PhD
Chief Technical Officer
Richard Cote, MD, FRCPath
Chief Medical Officer
Circulogix In The News
9.25.2017
Circulogix CSO Dr. Anthony Williams honored as a 2017 "Minority Scholar in Cancer Research" by AACR for work on disparate prostate cancer aggressiveness in African-American men.
http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=106&DetailItemID=638#.WiwbcbQ-f_Q
1.28.2015
Dr. Richard Cote - Circulogix, Inc CMO and Director of the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute at University of Miami (BioNIUM), and Dr. Ram Datar - CEO at Circulogix, Inc and Co-Director of BioNIUM, unveil South Florida's most expansive and advanced clean room facility for nano fabrication and biomedical research.
http://www.miamiherald.com/living/health-fitness/article8539388.html
6.13.2013
Circulogix CSO Anthony Williams secures the prestigious UNCF-Merck Science Initiative "Graduate Fellowship Award" to fund groundbreaking research in viable CTC culture characterization.
http://www.businesswire.com/news/home/20130613006129/en/37-African-American-Students-Awarded-Prestigious-UNCF%E2%80%A2Merck-Science
2.07.2012
Circulogix CEO Dr. Ram Datar receives the coveted "Jewel of India Award" for outstanding accomplishments and leadership in experimental and molecular pathology.
http://med.miami.edu/news/dr.-ram-h.-datar-named-to-prestigious-hind-rattan-award
2.07.2012
Circulogix CMO Dr. Richard Cote named first Joseph R Coulter, Jr Endowed Chair of Pathology at The University of Miami.
http://med.miami.edu/news/richard-cote-m.d.-named-first-joseph-r.-coulter-jr.-endowed-chair-in-pathol
Connect With Us
Follow us using the links below for all of the latest updates on Circulogix products, new developments and most recent and exciting research findings
Email
info@circulogixinc.com
LinkedIn
Under Construction
Twitter
Under Construction
Facebook
Under Construction
